Agency recommends physicians closely examine Botox packaging
MONDAY, April 20, 2015 (HealthDay News) — Counterfeit Botox may have been distributed to doctors’ offices and medical clinics across the United States, the U.S. Food and Drug Administration warns.
The counterfeit Botox — which is considered unsafe and should not be used — was sold by an unlicensed supplier not authorized to ship or distribute drug products in the United States, the FDA said in a news release.
Packaging similarities between the fakes and the FDA-approved Botox, which is made by Allergan (100 units/vial), could cause health care professionals to mistake one for the other. Approved Botox displays the active ingredient as “OnabotulinumtoxinA” on the outer carton and vial, the FDA said. The outer carton of the counterfeit version says the active ingredient is “Botulinum Toxin Type A” instead of “OnabotulinumtoxinA.” The FDA said the counterfeit product also can be identified in other ways. For instance, the vial is missing the lot number.
Health care professionals should check with Allergan to confirm that the distributor that provided the Botox is authorized to sell the product, the FDA said. Allergan’s website lists authorized Botox suppliers. Suspected counterfeit Botox products should be reported to the FDA. There are no known cases of people harmed by the counterfeit version of Botox, the FDA noted. The approved product by Allergan is considered safe.
Copyright © 2015 HealthDay. All rights reserved.
